Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Daniel Maslyar"'
Autor:
Michael Ward, Lawrence P. Carter, Julie Y. Huang, Daniel Maslyar, Balasubrahmanyam Budda, Robert Paul, Arnon Rosenthal
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 1, Pp n/a-n/a (2024)
Abstract INTRODUCTION Heterozygous mutations in the GRN gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab is a human monoclonal
Externí odkaz:
https://doaj.org/article/dd511265638b4ca39288d8acd272d8a6
Autor:
Lovingly Park, Daniel Maslyar, Michael Ward, Felix Yeh, Hua Long, Michael Kurnellas, Mayura Vadhavkar, Balasubrahmanyam Budda
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::199ad24ab7faad2d3c092dc072808fc7
https://doi.org/10.1212/wnl.0000000000202638
https://doi.org/10.1212/wnl.0000000000202638
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Supplementary Figure S1. CA125 response to lifastuzumab vedotin in ovarian cancer patients. All patients with radiographic responses also had {greater than or equal to}50 decrease in CA125 from baseline levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38becf22c0cb4090fc7526cc5dc5f7b1
https://doi.org/10.1158/1078-0432.22474400.v1
https://doi.org/10.1158/1078-0432.22474400.v1
Autor:
Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Sandra M. Sanabria Bohorquez, Henk M.W. Verheul, Marjolijn N. Lub-de Hooge, Alphons H.H. Bongaerts, Carolien P. Schröder, Jourik A. Gietema, Johan R. de Jong, Daniel Maslyar, Bernard M. Fine, Simon P. Williams, Otto S. Hoekstra, Johannes Voortman, Michiel M. Smeenk, Frederike Bensch, Eva J. ter Weele, Catharina W. Menke-van der Houven van Oordt, Laetitia E. Lamberts
A. PET uptake in the circulation per cohort, as determined by region of interest drawn in left ventricle; cohort 1 (in blue) contained 2 patients (0 mg additional MMOT0530A), cohort 2 (in green) contained 9 patients (10 mg additional MMOT0530A). On X
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6a314ccf787656ae04a63b18bde4dd
https://doi.org/10.1158/1078-0432.22458321
https://doi.org/10.1158/1078-0432.22458321
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Purpose:This phase I trial assessed the safety, tolerability, and preliminary antitumor activity of lifastuzumab vedotin (LIFA), an antibody–drug conjugate of anti-NaPi2b mAb (MNIB2126A) and a potent antimitotic agent (monomethyl auristatin E).Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcfaf1467d4088929a6f4be22f3b838
https://doi.org/10.1158/1078-0432.c.6528776.v1
https://doi.org/10.1158/1078-0432.c.6528776.v1
Autor:
Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Sandra M. Sanabria Bohorquez, Henk M.W. Verheul, Marjolijn N. Lub-de Hooge, Alphons H.H. Bongaerts, Carolien P. Schröder, Jourik A. Gietema, Johan R. de Jong, Daniel Maslyar, Bernard M. Fine, Simon P. Williams, Otto S. Hoekstra, Johannes Voortman, Michiel M. Smeenk, Frederike Bensch, Eva J. ter Weele, Catharina W. Menke-van der Houven van Oordt, Laetitia E. Lamberts
Supplementary figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ef26cb450220d27c5dfc44e4602fc7
https://doi.org/10.1158/1078-0432.22458312
https://doi.org/10.1158/1078-0432.22458312
Autor:
Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Sandra M. Sanabria Bohorquez, Henk M.W. Verheul, Marjolijn N. Lub-de Hooge, Alphons H.H. Bongaerts, Carolien P. Schröder, Jourik A. Gietema, Johan R. de Jong, Daniel Maslyar, Bernard M. Fine, Simon P. Williams, Otto S. Hoekstra, Johannes Voortman, Michiel M. Smeenk, Frederike Bensch, Eva J. ter Weele, Catharina W. Menke-van der Houven van Oordt, Laetitia E. Lamberts
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e29461be5dbc9c9e17a74a4422077d
https://doi.org/10.1158/1078-0432.c.6523902.v1
https://doi.org/10.1158/1078-0432.c.6523902.v1
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Supplementary Figure S2. Representative NaPi2b ICH images for PROC and NSCLC patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4792574451e294405cc4ee7c39e46f
https://doi.org/10.1158/1078-0432.22474397
https://doi.org/10.1158/1078-0432.22474397
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Supplementary Table S1. Adverse events regardless of relationship to study drug occurring in 10 or more patients Supplementary Table S2. Adverse events grades 3-5 regardless of relationship to study drug occurring in 2 or more patients Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e868350c55d17cd24a597cdfc33a2e3
https://doi.org/10.1158/1078-0432.22474394.v1
https://doi.org/10.1158/1078-0432.22474394.v1
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f78d76adb36d813c09a31d6a8fef84c
https://doi.org/10.1136/jitc-2022-sitc2022.0114
https://doi.org/10.1136/jitc-2022-sitc2022.0114